Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra and currently employs 523 full-time employees. The company went IPO on 2005-05-26. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. The company also focuses on specialty chemicals. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.
16 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.